No Data
Ribomic, Stella Pharma, and others.
<3070> Issuance of new shares through Amagasa third-party allocation (6 million shares), issuance of the 4th subscription rights (potential shares of 18 million shares, amount raised of approximately 0.936 billion yen) <4591> Ribomic signs joint research agreement with University of Tokyo on ophthalmic diseases <4888> Stella Pharma, large exercise of the 4th subscription rights (with revision clause for exercise price), delivery of 0.534 million 4000 shares from 12th <9235> Introducing shareholder benefits program for Net Advertisement sales
Glad Cube, C&S, and others.
<3479> Revision above, expected operating profit for this term is 8.2 billion yen ← 7.35 billion yen. <4076> Established medium-term management plan for the term from May 25, 2027 to May 25, 2027, with a sales target of 10 billion yen for the term ending May 25, 2027. <4883> Mass exercise of 12th new share subscription rights (with exercise price adjustment clause) from Modalis, the number of shares to be awarded from the 11th, 0.85 million shares. Large-scale exercise of the first unsecured convertible bond type new share subscription rights with conversion price adjustment clause, with the number of shares to be awarded from the 3rd, 1.42 million 8568 shares.
The Tokyo Stock Exchange's Gross Index has been slightly up for 4 consecutive days, generally showing a steady movement in the afternoon with active bioscience stock picking.
On the Growth Market of the Tokyo Stock Exchange, the market index rose slightly for the fourth consecutive day, with the Growth Market Index at 848.64 (+2.01) and a volume of 0.22417 billion shares, amounting to JPY 113.9 billion. The Growth Market 250 Index was also up slightly at 658.93 (+1.48), with a volume of 0.17788 billion shares traded for JPY 85.3 billion. There were 261 gainers, 278 losers, and 46 unchanged. The Dow Jones Industrial Average rose $67.87 in the U.S. market on the 5th day.
MFS, United & Collective, etc.
<196A> MFS SMBC Nikko Securities Inc. shareholding ratio -% → 7.10%, report obligation expiration date on June 28, 2024 <206A> PRISM BioLab Co., Ltd., Kiichiro Nakashima shareholding ratio -% → 5.29%, report obligation expiration date on July 2, 2024 <206A> PRISM BioLab Co., Ltd., Eli Lilly and Company shareholding
Volume change rate ranking (2pm) - Dai Dorymi, Euglena and others ranked.
* In the volume change rate ranking, you can understand the interest of market participants, such as the trend of exploration, by comparing the volume of the past 5 days with the volume on the day of delivery. * Top volume change rate [ as of July 5th, 14:32 ] (comparison of average volume over the past 5 days) Stock code Stock name Volume 5 day average volume Volume change rate Stock price change rate <3205> Dai-Dri-Mi 14671200 534516.26 340.07% 0.158
SMBC Nikko Securities decrases its stake in Stella Pharma(4888.JP) to 4.61%
On Jul 5, SMBC Nikko Securities submitted the Change Report to Ministry of Finance. The report shows that SMBC Nikko Securities decreased their holdings in $Stella Pharma(4888.JP)$, with their joint s
No Data
